Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PAX6 promotes neuroendocrine phenotypes of prostate cancer via enhancing MET/STAT5A-mediated chromatin accessibility.

Journal of experimental & clinical cancer research : CR - 15 May 2024

Jing Nan, Du Xinxing, Liang Yu, Tao ZhenKeke, Bao Shijia, Xiao Huixiang, Dong Baijun, Gao Wei-Qiang, Fang Yu-Xiang

Abstract excerpt

BACKGROUND: Neuroendocrine prostate cancer (NEPC) is a lethal subset of prostate cancer which is characterized by neuroendocrine differentiation and loss of androgen receptor (AR) signaling. Growing evidence reveals that cell lineage plasticity is crucial in the failure of NEPC therapies. Although studies suggest the involvement of the neural transcription factor PAX6 in drug resistance, its specific role in NEPC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Chromatin

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to PAX6 Transcription Factor

Share to Prostatic Neoplasms

Share to Proto-Oncogene Proteins c-met

Share to Signal Transduction

Share to STAT5 Transcription Factor

Source

Open in PubMed Open full text

Identifiers

PMID: 38745318
DOI: 10.1186/s13046-024-03064-1
PMCID: PMC11094950

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PAX6 promotes neuroendocrine phenotypes of prostate cancer via enhancing MET/STAT5A-mediated chromatin accessibility.PMID 38745318Read ↗

Understanding the function of Pax5 in development of docetaxel-resistant neuroendocrine-like prostate cancersSemantic proximity Read ↗

Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate CancerSemantic proximity Read ↗

Understanding the role of Pax5 in development of taxane-resistant neuroendocrine like prostate cancersSemantic proximity Read ↗

Role of transcription factors and chromatin modifiers in driving lineage reprogramming in treatment-induced neuroendocrine prostate cancerSemantic proximity Read ↗

Alternative RNA splicing of the MEAF6 gene facilitates neuroendocrine prostate cancer progressionSemantic proximity Read ↗

Role of MicroRNAs in Neuroendocrine Prostate CancerSemantic proximity Read ↗

The Many Faces of Neuroendocrine Differentiation in Prostate Cancer ProgressionSemantic proximity Read ↗

Targeting Key Players of Neuroendocrine Differentiation in Prostate CancerSemantic proximity Read ↗

The epigenetic and transcriptional landscape of neuroendocrine prostate cancerSemantic proximity Read ↗

The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approachesSemantic proximity Read ↗

N-Myc–mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancerSemantic proximity Read ↗

Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolutionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.